Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) will be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.31 per share for the quarter. Catalyst Pharmaceuticals has set its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million during the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. On average, analysts expect Catalyst Pharmaceuticals to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Catalyst Pharmaceuticals Trading Up 1.8 %

Shares of CPRX opened at $14.99 on Tuesday. Catalyst Pharmaceuticals has a 12-month low of $11.09 and a 12-month high of $17.76. The company has a market capitalization of $1.77 billion, a PE ratio of 24.57, a price-to-earnings-growth ratio of 0.81 and a beta of 0.89. The business’s 50 day moving average is $15.67 and its 200 day moving average is $14.73.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 25,000 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $15.68, for a total transaction of $392,000.00. Following the transaction, the director now owns 348,874 shares in the company, valued at $5,470,344.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Bank of America initiated coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They set a “buy” rating and a $23.00 price objective for the company. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Cantor Fitzgerald restated an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $26.43.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.